. >> 1% this morning, novo nordisk and gsk leading that sector higher.he banks also catching a strong bid. this morning. santander driving that sector higher. on the downside this morning. here's the picture of the underperformers. you've got autos down 1.4%. >> yesterday we saw a major. >> rebound in the european auto makers. the basket rose about 2% yesterday as investors again grew a little bit less concerned around the tariff outlook. and that provided some support for the sector. but today we're seeing money come back out of that basket of stocks. technology also under some selling pressure this morning that basket down about 8/10 of a percent. alphabet shares perhaps weighing on sentiment in the overall sector. taking a look at the individual stocks i mentioned a couple of the big movers already. >> but here's a. >> look for you at how. the big earners are shaping up today. novo nordisk up 3%, gsk up 5.5%. so a lot of focus on the pharma sector. let's dive straight into those novo earnings. the company posted. >> a. >> fourth quarter beat on the to

yeah for. >> gsk you know started. >> off 2024. >> very very strong.n they had some setbacks. >> with their vaccines. >> business where there are new rsv vaccine. >> in the united states. >> it. >> was limited. >> to a smaller population. >> so sales on that were. >> down quite a bit last year. >> of course, as a vaccines company. and the headlines of what. >> may happen. >> in the us. >> but yesterday. >> they delivered. >> a very, very. >> clean quarter. obviously the buyback was very unexpected. >> and the reason. >> we're still neutral. >> though, is that they do have a patent cliff for their hiv drugs that will be coming towards the end of this decade. and we just want to see more out of the pipeline to see if they're going to. >> be. >> able to offset that patent. cliff, let me ask you about the us and the administration and the. >> changes we're expecting there. to what extent. >> are you seeing european pharma investors deterred from the sector, and what is your view? how cautious should european pharma investors be about the outlook there? yea